A review on COVID-19 vaccinations

Garg, Ketan; Talwar, Dipesh; Mahajan, SamikshaNaresh; Karim, Sana; Prajapati, Kesar; Patel, Savan; Garg, Bhawna

doi:10.4103/bbrj.bbrj_280_21

Cited by 9 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notwithstanding, most of the authorized vaccines for COVID-19 are still amongst the phase 3 of the clinical trials which have not accomplished the phase 4 and subsequently restrict our knowledge regarding serious or long-term vaccine side-effect [ 1 , 8 ]. Whilst most of the vaccine complications are mainly a result of incubation processes and human immune system response interactions which are mild and self-limited, some cases faced with more challenging side-effects such as thromboembolic events [ 1 , 5 , 9 ]. In a vast study in courtiers of European Union on complication of viral-vector vaccine (AstraZeneca), a total of 250 VITT cases were detected whom majority of them (67%) were diagnosed with cerebral venous sinus thrombosis (CVST).…”

Section: Discussionmentioning

confidence: 99%

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

Zaheri¹,

Kiani

Afaghi

et al. 2022

Arch Clin Cases

View full text Add to dashboard Cite

The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

Zaheri¹,

Kiani

Afaghi

et al. 2022

Arch Clin Cases

View full text Add to dashboard Cite

show abstract

“…This crisis spurred global efforts to develop vaccines against COVID-19, marking a significant milestone in combating the virus. In response to the devastating impact of the virus, researchers and pharmaceutical companies swiftly developed and commercialized several significant vaccines against COVID-19 [ 3 , 4 ]. Among the first to receive emergency use authorization was Pfizer-BioNTech's BNT162b2, which demonstrated high efficacy rates in clinical trials [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Statistical Assessment of the Effectiveness of Multiple COVID-19 Vaccinations on Daily Confirmed Cases in Seoul City

Kim,

Jung

2024

Cureus

View full text Add to dashboard Cite

This study investigates the effectiveness of multiple COVID-19 vaccinations on daily confirmed cases in Seoul City. Utilizing comprehensive data on vaccinated individuals and confirmed cases sourced from the official website of the Korean Ministry of the Interior and Safety, we conducted detailed statistical analyses to assess the impact of each vaccination dose. The study covers data from April 21, 2021, to September 29, 2022. Statistical multiple linear regression was employed to analyze the relationship between daily confirmed cases (positive outcomes from PCR tests) and multiple vaccine doses, using p-values as the criteria for determining the effectiveness of each dose. The analysis included data from four vaccination doses.The analysis reveals that the first, second, and third doses of the COVID-19 vaccines have a statistically significant positive effect associated with the daily confirmed cases. However, the study finds that the fourth dose does not show a statistically significant impact on the reduction of daily confirmed cases. This suggests that while the initial three doses are crucial for establishing and maintaining high levels of immunity, the incremental benefit of subsequent doses may diminish.

show abstract

The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein

Iravanpour,

Farrokhi,

Jafarinia

et al. 2023

Human Cell

View full text Add to dashboard Cite

A review on COVID-19 vaccinations

Cited by 9 publications

References 26 publications

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

Statistical Assessment of the Effectiveness of Multiple COVID-19 Vaccinations on Daily Confirmed Cases in Seoul City

The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein

Contact Info

Product

Resources

About